Risultati della ricerca - M. Beksac

P05 ACETYL SALICYLIC ACID INDUCES POLARIZATION OF MACROPHAGES AND CYTOTOXICITY ON MYELOMA CELLS IN VITRO di N. Gonulkirmaz, M. Beksac, T. Ozkan, I. Kar, A. Sunguroglu

Testo

B02 | THE PROGNOSTIC IMPACT OF BONE MARROW PLASMA CELL INFILTRATION AT DIAGNOSIS IN AL AMYLOIDOSIS di K. Aslantaş, Ş. Özlü, I. Kuzu, M. Beksaç, G. Cengiz Seval

Testo

P24 | APPROACHING CURE IN MULTIPLE MYELOMA: A DUAL-CENTER EXPERIENCE AMONG PATIENTS DIAGNOSED BEFORE 2010 di G. Cengiz Seval, H. Aytekin, T. Otlu, U. Calıs, M. Beksac

Testo

P15 VALIDATION OF THE NOVEL EUROPEAN MYELOMA NETWORK PROGNOSTIC SCORE (R2-ISS) IN AN INDEPENDENT REAL-WORLD SETTING di G Cengiz Seval, M Aydoğan, MH Akbulut, B Karakaya, G Yavuz, H Yilmaz, M Beksac

Testo

P901: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN LENALIDOMIDE–PRETREATED MULTIPLE MYELOMA: A SUBANALYSIS OF OPTIMISMM BY FRAILTY di A. Oriol, M. Dimopoulos, F. Schjesvold, M. Beksac, M. Yagci, A. Larocca, S. Guo, Y. Mu, K. Hong, S. Dhanasiri, P. Richardson, K. Weisel

Testo

P73 | TP53 MUTATION AND MSS-WM IDENTIFY HIGH RISK WALDENSTROM MACROGLOBULINEMIA IN A REAL WORLD COHORT di U. Calis, S. Yuksel, M. Kurt Yuksel, P. Topcuoglu, I. Kuzu, O. Arslan, M. Ozcan, T. Demirer, S. Kocak Toprak, M. Beksac, G. Cengiz Seval

Testo

P19 EXTERNAL VALIDATION OF THREE EXISTING EARLY MYELOMA RELAPSE SCORES (BY EBMT, CIBMTR, AND GIMEMA) IN A SINGLE CENTER SHOWS MAJOR DIFFERENCES di M Beksac, G Cengiz Seval, S Civriz Bozdag, SK Toprak, M Kurt Yuksel, P Topcuoglu, O Arslan, M Ozcan, T Demirer, O Ilhan, G Gurman

Testo

PB2074: IBRUTINIB AS A PROMISING TREATMENT FOR WALDENSTRÖM MACROGLOBULINEMIA di O. Ilhan, G. Cengiz Seval, F. Avcu, B. Ferhanoglu, M. Ozcan, G. Cetin, E. Kurtoglu, H. Yilmaz, F. Atalay, E. Gulturk, M. Nalcaci, M. Beksac

Testo

P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE... di P Sonneveld, A Chanan-Khan, K Weisel, AK Nooka, T Masszi, M Beksac, I Spicka, V Hungria, M Munder, MV Mateos, TM Mark, MD Levin, T Ahmadi, X Qin, W Garvin Mayo, X Gai, J Carey, R Carson, A Spencer

Testo

C002 | SUBCUTANEOUS DARATUMUMAB + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE WITH DARA + LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NDMM: ANALYSIS OF SUSTAINED MINIMA... di E. Antonioli, P. Moreau, P. Sonneveld, H. Einsele, H. Quach, P. Joy Ho, M. Beksac, C. Hulin, X. Leleu, S. Mangiacavalli, A. Perrot, M. Cavo, A. Belotti, A. Broijl, H. Pei, A. Sitthi-Amorn, R. L. Carson, P. Rodríguez-Otero, M.A. Dimopoulos, M. Boccadoro

Testo

DP111 | POSITRON EMISSION TOMOGRAPHY WITH COMPUTED TOMOGRAPHY AND MINIMAL RESIDUAL DISEASE FOR EFFICACY ASSESSMENT IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: IMROZ... di E. Zamagni, T. Facon, M.A. Dimopoulos, X. Leleu, M. Beksac, L. Pour, R. Hajek, Z. Liu, J. Minarik, P. Moreau, J. Romejko-Jarosinska, I. Spicka, T.G. Martin, L. Qiu, C. Sachpekidis, E. Kodas, H. Van De Velde, L. Zhao, R. Orlowski, H. Goldschmidt

Testo

P12 | SUBCUTANEOUS DARATUMUMAB (DARA) + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE WITH DARA + LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MY... di P. Sonneveld, Ph. Moreau, H. Einsele, H. Quach, P.J. Ho, M. Beksac, C. Hulin, E. Antonioli, X. Leleu, S. Mangiacavalli, A. Perrot, M. Cavo, A. Belotti, A. Broijl, H. Pei, A. Sitthi-Amorn, R.L. Carson, P. Rodríguez-Otero, M.A. Dimopoulos, M. Boccadoro

Testo

DP114 | ISATUXIMAB, BORTEZOMIB, LENALIDOMIDE, DEXAMETHASONE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MYELOMA AND PLASMACYTOMAS: IMROZ SUBGROUP ANALYSIS di E. Zamagni, T. Facon, M.A. Dimopoulos, X. Leleu, M. Beksac, L. Pour, R. Hajek, Z. Liu, J. Minarik, P. Moreau, J. Romejko-Jarosinska, I. Spicka, V. Vorobyev, T.G. Martin, L, Qiu, C. Sachpekidis, E. Kodas, Z. Klippel, U. Khan, H. Van De Velde, R. Z. Orlowski, H. Goldschmidt

Testo

P957: CARFILZOMIB, LENALIDOMIDE, DEXAMETHASONE FOLLOWED BY A SECOND AUTO-HCT IS AN EFFECTIVE STRATEGY IN FIRST RELAPSE MULTIPLE MYELOMA: A STUDY OF THE CHRONIC MALIGNANCIES WORKING... di R. Tilmont, I. Yakoub-Agha, D.-J. Eikema, N. Zinger, M. Haenel, N. Schaap, C. Herrera Arroyo, C. Schuermans, W. Bethge, M. Engelhardt, J. Kuball, M. Michieli, N. Schub, K. M. O. Wilson, J. H. Bourhis, M. V. Mateos, N. Robin, E. Jost, N. Kröger, J. M. Moraleda, S. Sica, P. J. Hayden, M. Beksac, S. Schönland, S. Manier

Testo

B09 | DARATUMUMAB MONOTHERAPY VERSUS ACTIVE MONITORING IN PATIENTS WITH HIGH-RISK SMOLDERING MULTIPLE MYELOMA: "AQUILA" OUTCOMES BASED ON MAYO 2018/IMWG 2020 RISK STRATIFICATION,... di F. Schjesvold, P.M. Voorhees, M.A. Dimopoulos, Y.C. Cohen, V. Hungria, I. Sandhu, J. Lindsay, R.I. Baker, K. Suzuki, H. Kosugi, M-D. Levin, M. Beksac, K. Stockerl-Goldstein, H. Magen, A. Oriol, G. Mikala, G. Garate, K. Theunissen, I. Spicka, A.K. Mylin, S. Hallam, S. Bringhen, K. Uttervall, B. Pula, A.M. Khan, E. Medvedova, J.C. Ye, A.J. Cowan, Ph. Moreau, M-V. Mateos, H. Goldschmidt, D. Vieyra, A. Raval, L. Sha, L. Li, E. Rousseau, R.M. Dennis, R.L. Carson, S.V. Rajkumar

Testo